At a glance
ClinicalIndex Comparison RecordN/ACompleted· 26 enrolled
Drug / intervention
dexamethasone intravitreal implant 0.7 mgdrug
Likely dose
dexamethasone intravitreal implant 0.7 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein Occlusion
In Brief
An observational study evaluating dexamethasone intravitreal implant 0.7 mg for Retinal Vein Occlusion and Macular Oedema. Completed, enrolled 26 participants across 1 site.
Detailed Summary
The purpose of this study is to use retrospective data to evaluate the efficacy, safety and re-injection interval of OZURDEX® in the treatment of macular oedema due to retinal vein occlusion (RVO) in patients who received OZURDEX® as part of the Belgium Medical Needs Program.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRetinal Vein Occlusion, Macular Oedema
CountriesBelgium
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2012
First PostedMar 2012
Primary CompletionJun 2012
TodayJul 2026
First PostedMar 29, 2012
Enrollment StartMar 1, 2012
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 14.3 years ago
Interventions
dexamethasone intravitreal implant 0.7 mgdrug
OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.